Gqapping up
Gapping up
In reaction to strong earnings/guidance: MDXG +12.3%,
NAV +6.3%,
FDX +5.3%,
JBL +2%,
RAD +1.3%,
APC +0.9%
M&A news: AVP +24% (near a deal to sell an 80% stake in its North American unit and ~17% equity stake to PE firm Cerberus, according to the WSJ).
Other news: OCLS +25.5% (receives FDA Microcyn-Based SebDerm Gel),
ATNM +20% (reports the FDA has cleared its IND filing for Iomab-B; will proceed with a pivotal, Phase 3 clinical trial),
P +18.7% (confirmed the CRB ruling, musicians and record labels will see royalties from Pandora increase 15%),
ATOS +18.4% ( discloses Stock Purchase Agreement with the National Reference Laboratory for Breast Health),
MNGA +10.5% (selected to be part of $100 mln Kennedy space center project; first purchase order received),
ASTI +9.9% (reports an update on its adjourned stockholder meeting and NASDAQ status; believes a quorum will be present at the Friday meeting),
GLPG +7.6% (Galapagos NV and Gilead Sciences (GILD) form global partnership to develop Filgotinib),
GEVO +6.6% (announces update on the certification process related to its alcohol to jet product),
ENPH +6.3% (cont strength),
SUNE +5.2% (cont strength),
KTOV +5.2% (Sheer Roichman discloses a 14.76% passive stake via a 13G filing),
CANF +5% (announced that the Japan Patent Office has granted the co a patent for its lead drug candidate CF101),
MBLY +4% (rebounding pre-mkt following yday's declines),
HZNP +3.5% (initiated with a Buy at Goldman),
TSEM +3% (signs agreement with Semiconductor Laboratory to provide process engineering and equipment maintenance; to generate revs of ~$35 mln),
UPS +2.4% (following FDX earnings),
ANIP +1.8% (announces FDA approval of its 17mg/scoopful, Polyethylene Glycol 3350 powder),
BBEP +1.6% ( reports its interim estimated total proved reserves; as of November, firm has $1.87 bln in total interim reserves),
KNDI +1.4% (cont strength)
Analyst comments: RUN SCTY +6.2% (upgraded to Outperform at Bernstein),
+6% (upgraded to Overweight from Sector Weight at KeyBanc Capital Mkts),
DDD +4.8% (upgraded to Overweight from Equal Weight at a boutique firm),
MU +3.4% (upgraded to Overweight from Equal-Weight at Morgan Stanley),
FINL +3.1% (upgraded to Buy from Neutral at Citigroup),
RLYP +3.1% (initiated with a Buy at H.C. Wainwright; tgt $63 ),
GERN +2.8% (initiated with a Buy at Janney),
QCOM +2.2% (upgraded to Overweight from Neutral at JP Morgan),
COMM +1.8% (upgraded to Overweight from Neutral at JP Morgan),
MYL +1.3% (added to Conviction Buy List at Goldman)